Pancreatic Ductal Adenocarcinoma Pipeline Insights, Clinical Trials Assessment, FDA Approvals, Emerging Therapies and Companies | DelveInsight

DelveInsight's, "Pancreatic Ductal Adenocarcinoma Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Pancreatic Ductal Adenocarcinoma Research. Learn more about our innovative pipeline today! @ Pancreatic Ductal Adenocarcinoma Pipeline Outlook- https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report
• In January 2025:- Cardiff Oncology:- The main objective of this trial is to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC).
• In January 2025:- Genentech Inc.:- The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
• In January 2025:- Arcus Biosciences Inc.:- The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients. A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma
• DelveInsight's Pancreatic Ductal Adenocarcinoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma treatment.
• The leading Pancreatic Ductal Adenocarcinoma Companies such as Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.
• Promising Pancreatic Ductal Adenocarcinoma Therapies such as Zimberelimab, Quemliclustat, Onvansertib, Nanoliposomal irinotecan, Leucovorin, mFOLFIRINOX, and others.

Stay informed about the cutting-edge advancements in Pancreatic Ductal Adenocarcinoma Treatments. Download for updates and be a part of the revolution in oncology care @ Pancreatic Ductal Adenocarcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pancreatic Ductal Adenocarcinoma Emerging Drugs Profile

• Onvansertib: Cardiff Oncology
Onvansertib, an oral highly-selective PLK1 inhibitor, which we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC.

• Nadunolimab: Cantargia
Nadunolimab is a humanised monoclonal antibody lacking fucose, being developed by Cantargia, for the treatment of solid tumours, including non-small cell lung cancer (NSCLC) and pancreatic cancer. Nadunolimab is a first-in-class anti-IL1RAP antibody, currently evaluated with standard of care chemotherapy or checkpoint inhibitor in five phase I/II clinical trials with a primary focus on PDAC and NSCLC. Nadunolimab induces ADCC and blocks signaling of both IL-1α and IL-1β, counteracting thecontribution of IL-1 to the immune suppressive tumor microenvironment and development of resistance to chemotherapy

• Zimberelimab: Arcus Biosciences
Zimberelimab is a monoclonal antibody that binds pd-1 restoring the antitumor activity of T-cells. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with The most advanced study with zimberelimab is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic. Zimberelimab is also being evaluated as monotherapy in a tumor agnostic, biomarker-selected Phase 1b trial for cancers with no approved anti-PD-1 treatment options. full line-of-sight to the commercialization of innovative therapies for all patients who may benefit.

Learn more about Pancreatic Ductal Adenocarcinoma Drugs opportunities in our groundbreaking A Pancreatic Ductal Adenocarcinoma Research and development projects @ Pancreatic Ductal Adenocarcinoma Unmet Needs- https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pancreatic Ductal Adenocarcinoma Companies
Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Oral
• Intravenous
• Subcutaneous

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Discover the latest advancements in Pancreatic Ductal Adenocarcinoma Treatment by visiting our website. Stay informed about how we're transforming the future of oncology disease @ Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Pancreatic Ductal Adenocarcinoma Pipeline Report
• Coverage- Global
• Pancreatic Ductal Adenocarcinoma Companies- Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.
• Pancreatic Ductal Adenocarcinoma Therapies- Zimberelimab, Quemliclustat, Onvansertib, Nanoliposomal irinotecan, Leucovorin, mFOLFIRINOX, and others.
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Pancreatic Ductal Adenocarcinoma Pipeline on our website @ Pancreatic Ductal Adenocarcinoma Drugs and Companies- https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Pancreatic Ductal Adenocarcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pancreatic Ductal Adenocarcinoma- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. NIS 793: XOMA
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CEND 1: Cend Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. DCC-3116: Deciphera Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. RMC-6236: REVOLUTION Medicines
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Pancreatic Ductal Adenocarcinoma Key Companies
21. Pancreatic Ductal Adenocarcinoma Key Products
22. Pancreatic Ductal Adenocarcinoma- Unmet Needs
23. Pancreatic Ductal Adenocarcinoma- Market Drivers and Barriers
24. Pancreatic Ductal Adenocarcinoma- Future Perspectives and Conclusion
25. Pancreatic Ductal Adenocarcinoma Analyst Views
26. Pancreatic Ductal Adenocarcinoma Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2025

varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
vascular access devices market- https://www.delveinsight.com/report-store/vascular-access-device-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
myeloproliferative neoplasms market- https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
NK cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
testicular neoplasm market- https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight
phototherapies for psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
skin neoplasm market- https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
cardiac implantable electronic devices market- https://www.delveinsight.com/blog/implantable-cardiac-monitors-market
dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-epidemiology-forecast-insight
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
catheter stabilization devices market- https://www.delveinsight.com/sample-request/catheter-stabilization-securement-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.